Stealth BioTherapeutics Corp
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Stealth BioTherapeutics Corp generated cash of -$44,971,000, which is more than the previous year. Cash used in financing activities reached the amount of $59,136,000 last year. Net change in cash is therefore $14,348,000.
Cash Flow
| 2016 | -54.01M | -182.52K | 50.29M |
|---|---|---|---|
| 2017 | -69.83M | -172.98K | 64.41M |
| 2018 | -72.07M | -11.65K | 78.82M |
| 2019 | -47.98M | -130K | 88.02M |
| 2020 | -53.53M | -60K | 35.61M |
| 2021 | -44.97M | 183K | 59.13M |
MITO Cash Flow Statement (2016 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 32.78M | 50.76M | 10.85M | 4.11M | 9.70M | 13.62M |
Operating activities | ||||||
Net income | -52.52M | -57.45M | -71.72M | -96.71M | -82.90M | -61.04M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 77K | 232K | 284K | 309.04K | 346.87K | 312.53K |
Stock-based compensation expense | 4.17M | 4.22M | 3.24M | 1.27M | 1.28M | 1.83M |
| Deferred income tax benefit | 4.17M | 4.22M | 3.24M | 1.27M | 1.28M | 1.83M |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -59K | -6.14M | -1.50M | 3.56M | 4.54M | 767.83K |
Cash generated by operating activities | -44.97M | -53.53M | -47.98M | -72.07M | -69.83M | -54.01M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -67K | -35K | -130K | -11.65K | -160.95K | -287.88K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 183K | -60K | -130K | -11.65K | -172.98K | -182.52K |
Financing activities | ||||||
Common Stock Issued | 8.97M | 23.43M | 88.01M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -9.11M | -7.48M | 0 | -686.54K | 0 | 0 |
Cash used in financing activities | 59.13M | 35.61M | 88.02M | 78.82M | 64.41M | 50.29M |
Net Change In Cash | 14.34M | -17.98M | 39.91M | 6.73M | -5.59M | -3.91M |
Cash at end of period | 47.13M | 32.78M | 50.76M | 10.85M | 4.11M | 9.70M |
| Data source | Data source | Data source | Data source |